Preclinical evaluation of [225Ac]Ac-PSMA-617 and in vivo effect comparison in combination with [177Lu]Lu-PSMA-617 for prostate cancer
This study shows that PSMA radioisotope therapy (RIT) and TAT combined therapy could improve patient management by delaying disease progression.
Authors
- Eduardo Savio (ORCID: https://orcid.org/0000-0002-2358-194X)
- Javier Giglio (ORCID: https://orcid.org/0000-0002-2297-6739)
- Leticia Reyes (ORCID: https://orcid.org/0000-0001-5967-5860)
- Lucia Alfaya
- Gianclaudio Falasco
- Rosina Dapueto (ORCID: https://orcid.org/0000-0001-7893-977X)
- Florencia Arredondo (ORCID: https://orcid.org/0000-0002-4462-8049)
- Paulo Schiavom Duarte (ORCID: https://orcid.org/0000-0003-4517-4410)
- Kevin Zirbesegger
- Juan Gambini (ORCID: https://orcid.org/0000-0001-8979-2865)
- Luis Urrutia
- Manuela Bentura
Institutions
- Centro Uruguayo de Imagenología Molecular (UY)
Publication Details
- Journal
- Nuclear Medicine and Biology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.nucmedbio.2025.109032
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- International Atomic Energy Agency